Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 214

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector

Open access
O’Hara, Geraldine A., Duncan, Christopher J. A., Ewer, Katie J., Collins, Katharine A., Elias, Sean C., Halstead, Fenella D., Goodman, Anna L., Edwards, Nick J., Reyes-Sandoval, Arturo, Bird, Prudence, Rowland, Rosalind, Sheehy, Susanne H., Poulton, Ian D., Hutchings, Claire, Todryk, Stephen, Andrews, Laura, Folgori, Antonella, Berrie, Eleanor, Moyle, Sarah, Nicosia, Alfredo, Colloca, Stefano, Cortese, Riccardo, Siani, Loredana, Lawrie, Alison M., Gilbert, Sarah C., Hill, Adrian V. S.·2012·The Journal of Infectious Diseases

Abstract

BACKGROUND: Vaccine development in human Plasmodium falciparum malaria has been hampered by the exceptionally high levels of CD8(+) T cells required for efficacy. Use of potently immunogenic human adenoviruses as vaccine vectors could overcome this problem, but these are limited by preexisting immunity to human adenoviruses. METHODS: From 2007 to 2010, we undertook a phase I dose and route finding study of a new malaria vaccine, a replication-incompetent chimpanzee adenovirus 63 (ChAd63) encoding the preerythrocytic insert multiple epitope thrombospondin-related adhesion protein (ME-TRAP; n = 54 vaccinees) administered alone (n = 28) or with a modified vaccinia virus Ankara (MVA) ME-TRAP booster immunization 8 weeks later (n = 26). We observed an excellent safety profile. High levels of TRAP antigen-specific CD8(+) and CD4(+) T cells, as detected by interferon γ enzyme-linked immunospot assay and flow cytometry, were induced by intramuscular ChAd63 ME-TRAP immunization at doses of 5 × 10(10) viral particles and above. Subsequent administration of MVA ME-TRAP boosted responses to exceptionally high levels, and responses were maintained for up to 30 months postvaccination. CONCLUSIONS: The ChAd63 chimpanzee adenovirus vector appears safe and highly immunogenic, providing a viable alternative to human adenoviruses as vaccine vectors for human use. CLINICAL TRIALS REGISTRATION: NCT00890019.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/infdis/jir850

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 214

Metadata

Authors
O’Hara, G. A., Duncan, C. J. A., Ewer, K. J., Collins, K. A., Elias, S. C., Halstead, F. D., Goodman, A. L., Edwards, N. J., Reyes-Sandoval, A., Bird, P., Rowland, R., Sheehy, S. H., Poulton, I. D., Hutchings, C., Todryk, S., Andrews, L., Folgori, A., Berrie, E., Moyle, S., Nicosia, A., Colloca, S., Cortese, R., Siani, L., Lawrie, A. M., Gilbert, S. C., & Hill, A. V. S.
Venue
The Journal of Infectious Diseases
Published
2012-01-24
Volume
205
Issue
5
Pages
772-781
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2105595963
Cited by
214
References
3
FWCI
27.49
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. https://app.cochat.ai/papers/10.1093/infdis/jir850
The paper
O’Hara, G. A., Duncan, C. J. A., Ewer, K. J., Collins, K. A., Elias, S. C., Halstead, F. D., Goodman, A. L., Edwards, N. J., Reyes-Sandoval, A., Bird, P., Rowland, R., Sheehy, S. H., Poulton, I. D., Hutchings, C., Todryk, S., Andrews, L., Folgori, A., Berrie, E., Moyle, S., . . . Hill, A. V. S. (2012). Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jir850

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.